Human Cathelicidin — Antimicrobial & Immune-Modulating Peptide for Infection Defense
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid peptide naturally produced by immune cells, epithelial cells, and barrier tissues. It serves as a first-line innate immune defense molecule with broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, while also modulating inflammatory and immune responses.
LL-37 disrupts microbial membranes through direct interaction with lipid bilayers, creating pores that kill bacteria, enveloped viruses, and fungi. Beyond its direct antimicrobial effects, LL-37 modulates immune function by recruiting immune cells to sites of infection, promoting wound healing, neutralizing bacterial endotoxins (LPS), and regulating pro-inflammatory cytokine production. It bridges innate and adaptive immunity.
| Parameter | Details |
|---|---|
| Starting Dose | 50 mcg daily |
| Standard Dose | 100 mcg daily |
| Acute / Loading Dose | 100–200 mcg daily (short-term) |
| Route | Subcutaneous injection |
| Cycle Length | 4–6 weeks standard; shorter courses for acute use |
| Onset | Immune support effects within days; full benefit over 2–4 weeks |
Review Required — Academy-Sourced Protocol
LL-37 dosing data is derived from Academy module references only. No standalone Matrix source PDF exists for this peptide. Protocol confirmation is pending clinical review. Dosing ranges reflect commonly reported clinical use — verify before implementation.
Clinical Note
Start low and titrate up, especially in patients with known chronic infections or high microbial burden. Die-off reactions can mimic worsening symptoms before improvement. Consider combining with Glutathione for detoxification support during treatment.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.